These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35051220)

  • 1. Overexpression of PD-1 and CD39 in tumor-infiltrating lymphocytes compared with peripheral blood lymphocytes in triple-negative breast cancer.
    Zahran AM; Rayan A; Zahran ZAM; Mohamed WMY; Mohamed DO; Abdel-Rahim MH; El-Badawy O
    PLoS One; 2022; 17(1):e0262650. PubMed ID: 35051220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prognostic Value of CD39 as a Marker of Tumor-Specific T Cells in Triple-Negative Breast Cancer in Asian Women.
    Meng J; Tan JYT; Joseph CR; Ye J; Lim JCT; Goh D; Xue Y; Lim X; Koh VCY; Wee F; Tay TKY; Chan JY; Ng CCY; Iqbal J; Lau MC; Lim HE; Toh HC; Teh BT; Dent RA; Tan PH; Yeong JPS
    Lab Invest; 2024 Mar; 104(3):100303. PubMed ID: 38103870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.
    Bottai G; Raschioni C; Losurdo A; Di Tommaso L; Tinterri C; Torrisi R; Reis-Filho JS; Roncalli M; Sotiriou C; Santoro A; Mantovani A; Loi S; Santarpia L
    Breast Cancer Res; 2016 Dec; 18(1):121. PubMed ID: 27912781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of tumor-reactive CD4
    Palomero J; Panisello C; Lozano-Rabella M; Tirtakasuma R; Díaz-Gómez J; Grases D; Pasamar H; Arregui L; Dorca Duch E; Guerra Fernández E; Vivancos A; de Andrea CE; Melero I; Ponce J; Vidal A; Piulats JM; Matias-Guiu X; Gros A
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36581331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumoral PD-1hiCD8+ T cells are partially exhausted and predict favorable outcome in triple-negative breast cancer.
    Guo L; Cao C; Goswami S; Huang X; Ma L; Guo Y; Yang B; Li T; Chi Y; Zhang X; Wu J
    Clin Sci (Lond); 2020 Apr; 134(7):711-726. PubMed ID: 32202617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial.
    Graeser M; Feuerhake F; Gluz O; Volk V; Hauptmann M; Jozwiak K; Christgen M; Kuemmel S; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kolberg-Liedtke C; Kates R; Wuerstlein R; Nitz U; Kreipe HH; Harbeck N
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression levels of co-inhibitory molecules CTLA-4, LAG-3, PD-1 and CD39 on CD4⁺ T cells correlate with progression of non-small cell lung cancer].
    Wei T; Zhang J; Wu Y; Zhang D; Lu L; Shen Q
    Zhonghua Zhong Liu Za Zhi; 2014 Jun; 36(6):424-9. PubMed ID: 25241783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-infiltrating CD39
    Qi Y; Xia Y; Lin Z; Qu Y; Qi Y; Chen Y; Zhou Q; Zeng H; Wang J; Chang Y; Bai Q; Wang Y; Zhu Y; Xu L; Chen L; Kong Y; Zhang W; Dai B; Liu L; Guo J; Xu J
    Cancer Immunol Immunother; 2020 Aug; 69(8):1565-1576. PubMed ID: 32306075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer.
    Laumont CM; Wouters MCA; Smazynski J; Gierc NS; Chavez EA; Chong LC; Thornton S; Milne K; Webb JR; Steidl C; Nelson BH
    Clin Cancer Res; 2021 Jul; 27(14):4089-4100. PubMed ID: 33963000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
    Tavares MC; Sampaio CD; Lima GE; Andrade VP; Gonçalves DG; Macedo MP; Cordeiro de Lima VC
    BMC Cancer; 2021 Aug; 21(1):901. PubMed ID: 34362334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.
    Ren X; Wu H; Lu J; Zhang Y; Luo Y; Xu Q; Shen S; Liang Z
    Cancer Biol Ther; 2018 May; 19(5):373-380. PubMed ID: 29336717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant Expression of CD39, CD69, and CD103 Identifies Antitumor CD8
    Lama GIG; Noél G; Márquez FCL; Galarza FFG; Hinojosa AIP; Rivera LEN; Willard-Gallo K; Astorga JRA
    Curr Pharm Biotechnol; 2024; 25(13):1747-1757. PubMed ID: 37680154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis.
    He TF; Yost SE; Frankel PH; Dagis A; Cao Y; Wang R; Rosario A; Tu TY; Solomon S; Schmolze D; Mortimer J; Lee P; Yuan Y
    PLoS One; 2020; 15(3):e0229955. PubMed ID: 32150594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High proportion of PD-1 and CD39 positive CD8+ tissue resident T lymphocytes correlates with better clinical outcome in resected human oesophageal adenocarcinoma.
    Hill SL; Sugiyarto G; Harrington J; James E; Underwood TJ; Elliott T
    Cancer Immunol Immunother; 2024 Sep; 73(11):213. PubMed ID: 39235606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of the CD8
    Li J; Huang HH; Tu B; Zhou MJ; Hu W; Fu YL; Li XY; Yang T; Song JW; Fan X; Jiao YM; Xu RN; Zhang JY; Zhou CB; Yuan JH; Zhen C; Shi M; Wang FS; Zhang C
    Front Immunol; 2021; 12():687296. PubMed ID: 34177939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8
    Canale FP; Ramello MC; Núñez N; Araujo Furlan CL; Bossio SN; Gorosito Serrán M; Tosello Boari J; Del Castillo A; Ledesma M; Sedlik C; Piaggio E; Gruppi A; Acosta Rodríguez EA; Montes CL
    Cancer Res; 2018 Jan; 78(1):115-128. PubMed ID: 29066514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer.
    Matsumoto H; Thike AA; Li H; Yeong J; Koo SL; Dent RA; Tan PH; Iqbal J
    Breast Cancer Res Treat; 2016 Apr; 156(2):237-47. PubMed ID: 26960711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
    Lee J; Kim DM; Lee A
    Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.
    Wang K; Shen T; Siegal GP; Wei S
    Hum Pathol; 2017 Nov; 69():110-117. PubMed ID: 28993275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.